Abivax presents first-half 2024 financial results
09 sept. 2024 16h01 HE
|
Abivax
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA...
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
06 août 2024 02h30 HE
|
Abivax
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the...
Abivax Provides Operational and Key Program Update
15 juil. 2024 16h00 HE
|
Abivax
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
04 juin 2024 16h10 HE
|
Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
07 mai 2024 16h00 HE
|
Abivax
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq:...
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
05 avr. 2024 16h00 HE
|
Abivax
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or...
Abivax reports 2023 financial results and operational update
02 avr. 2024 02h30 HE
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
07 févr. 2024 02h30 HE
|
Abivax
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...